Northwest & Ethical Investments L.P. Takes Position in Edwards Lifesciences Co. (NYSE:EW)

Northwest & Ethical Investments L.P. bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 75,308 shares of the medical research company's stock, valued at approximately $5,575,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP grew its stake in shares of Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares in the last quarter. Jennison Associates LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth about $555,939,000. Assenagon Asset Management S.A. grew its position in Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company's stock worth $314,182,000 after purchasing an additional 3,506,886 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $213,844,000. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Edwards Lifesciences by 239.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company's stock worth $243,745,000 after buying an additional 2,606,950 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 400 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total transaction of $27,792.00. Following the sale, the vice president now owns 22,588 shares in the company, valued at $1,569,414.24. This represents a 1.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 51,303 shares of company stock worth $3,715,776 in the last 90 days. Insiders own 1.29% of the company's stock.

Remove Ads

Edwards Lifesciences Trading Down 0.1 %

NYSE:EW traded down $0.06 during trading hours on Tuesday, hitting $71.29. The company had a trading volume of 6,112,449 shares, compared to its average volume of 4,612,307. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a market capitalization of $41.91 billion, a PE ratio of 10.23, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The stock has a 50-day moving average price of $71.43 and a 200 day moving average price of $70.42.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Citigroup raised their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and raised their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Barclays boosted their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Morgan Stanley lifted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. Finally, Truist Financial reiterated a "hold" rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.